{
    "clinical_study": {
        "@rank": "67538", 
        "arm_group": {
            "arm_group_label": "1", 
            "arm_group_type": "Experimental", 
            "description": "Iron chelating intervention"
        }, 
        "brief_summary": {
            "textblock": "Friedreich ataxia, an autosomal recessive condition, ascribed to frataxin gene expansion,\n      has been shown to result from an iron- induced injury to the mitochondrial respiratory\n      chain. Buffering free radicals with short-chain quinones (Idebenone) protects the patients\n      against cardiomyopathy but not CNS involvement. Removing CNS iron should limit the impact of\n      the neurological symptoms of the disease."
        }, 
        "brief_title": "Iron-Chelating Therapy and Friedreich Ataxia", 
        "completion_date": {
            "#text": "March 2008", 
            "@type": "Actual"
        }, 
        "condition": "Friedreich Ataxia", 
        "condition_browse": {
            "mesh_term": [
                "Ataxia", 
                "Friedreich Ataxia"
            ]
        }, 
        "detailed_description": {
            "textblock": "The current clinical trial is a monocentric open phase1-2 trial  in the context of rare\n      diseases framework, aimed to the goal of defining the tolerance/efficacy of the treatment.\n\n      Inclusion criteria: minimum age: 13 years Follow up in the Dept of Genetics, Hospital\n      Necker-Enfants Malades, Paris, France"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Minimum age: 13 years\n\n          2. Molecular confirmation of frataxin gene mutation\n\n          3. Iron overload evaluation\n\n          4. Presence of lactate\n\n          5. Echography response to Idebenone treatment\n\n          6. Urinary test of pregnancy for girls\n\n          7. Sexual abstinence for men\n\n          8. Information consent\n\n        Exclusion Criteria:\n\n          1. No disturbance of iron metabolism\n\n          2. No response to Idebenone\n\n          3. Friedreich not confirmed\n\n          4. Polynuclear neutrophils <2 x 109/L or hemoglobin < 8g/dL\n\n          5. No participation to other trial\n\n          6. Doubt regarding the compliance of the patient to protocol\n\n          7. Impossibility to undergo X-ray examination or presence of iron material in the\n             backbone\n\n          8. Pregnant women\n\n          9. Absence of social insurance."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 16, 2005", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00224640", 
            "org_study_id": "P041201", 
            "secondary_id": "PCR 05001"
        }, 
        "intervention": {
            "arm_group_label": "1", 
            "description": "Iron chelating intervention", 
            "intervention_name": "Iron chelating intervention", 
            "intervention_type": "Drug", 
            "other_name": "Iron chelating intervention"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Iron Chelating Agents", 
                "Iron"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Iron-chelating treatment", 
        "lastchanged_date": "March 3, 2009", 
        "location": {
            "facility": {
                "address": {
                    "city": "Paris", 
                    "country": "France", 
                    "zip": "75015"
                }, 
                "name": "Necker Hospital"
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Effect of Iron-Chelating Therapy in Friedreich Ataxia. Study Phase I/II", 
        "overall_official": {
            "affiliation": "Assistance Publique - H\u00f4pitaux de Paris", 
            "last_name": "Arnold MUNNICH, Pr,MD,PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "France: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "March 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "assessment of iron overload at TO and month2 by imagery", 
            "safety_issue": "No", 
            "time_frame": "at months :0, 1 ,2 ,4 ,6"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00224640"
        }, 
        "responsible_party": {
            "name_title": "Amel Ouslimany", 
            "organization": "Department Clinical Research  of Developpement"
        }, 
        "secondary_outcome": [
            {
                "measure": "Clinical (monthly) and biological parameter follow- up ( blood count,", 
                "safety_issue": "No", 
                "time_frame": "weekly"
            }, 
            {
                "measure": "plasma iron, ferritin, transferrin and liver enzymes)", 
                "safety_issue": "Yes", 
                "time_frame": "every months"
            }
        ], 
        "source": "Assistance Publique - H\u00f4pitaux de Paris", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Assistance Publique - H\u00f4pitaux de Paris", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2005", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2007"
    }
}